Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance

NCT01194336 · View on ClinicalTrials.gov ↗

Study Summary

The primary objective of this study is to determine whether huperzine A, donepezil, and galantamine impact militarily relevant aspects of neurocognitive performance in humans, compared to placebo.

Interventions

  • OTHER Placebo
  • DRUG Donepezil
  • DRUG Galantamine
  • DRUG Huperzine A

Study Locations (1)

Maryland

  • Walter Reed Army Institute of Research — Silver Spring

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2012-02
Est. Completion 2012-10

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01194336

The ClinicalTrials.gov registry entry for NCT01194336 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 49 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Biomarkers, Pharmacological appearing as the primary indexed condition, and to 4 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01194336 reports 1 study location spanning 1 distinct geographic area — top geographies include Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01194336 about?

NCT01194336 is a clinical study titled "Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance". The primary objective of this study is to determine whether huperzine A, donepezil, and galantamine impact militarily relevant aspects of neurocognitive performance in humans, compared to placebo.

What is the current status of trial NCT01194336?

This trial is currently completed. The enrollment target is 84 participants. The study started on 2012-02. Estimated completion is 2012-10.

What conditions does trial NCT01194336 study?

This clinical trial studies the following conditions: Biomarkers, Pharmacological. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01194336?

The interventions under investigation include: Placebo (OTHER), Donepezil (DRUG), Galantamine (DRUG), Huperzine A (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01194336?

This trial is sponsored by U.S. Army Medical Research and Development Command, which has 49 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01194336 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial